Reducing length of hospital stay with colchicine
Karakaş et al.,
Reducing length of hospital stay with colchicine,
The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with higher dosage (1mg/day vs 0.5mg/day). More control patients were on oxygen at baseline (65% vs. 54%).
This study is excluded in the after exclusion results of meta
analysis:
excessive unadjusted differences between groups.
risk of death, 12.7% lower, RR 0.87, p = 0.72, treatment 16 of 165 (9.7%), control 19 of 171 (11.1%), NNT 71.
|
risk of ICU admission, 16.0% lower, RR 0.84, p = 0.50, treatment 30 of 165 (18.2%), control 37 of 171 (21.6%), NNT 29.
|
hospitalization time, 25.0% lower, relative time 0.75, p < 0.001, treatment 165, control 171.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Karakaş et al., 31 Jan 2022, retrospective, Turkey, peer-reviewed, 11 authors, dosage 1mg daily, 0.5mg for 37 patients.
Abstract: Coronavirus Pandemic
Reducing length of hospital stay with colchicine
Özlem Karakaş1, Abdulsamet Erden1, Serdar Can Güven1, Berkan Armağan1, Enes Seyda Sahiner2,3, Ali
Can Kurtipek2,3, Osman Inan2,3, Emin Gemcioglu2,3, İhsan Ateş2, Ahmet Omma1, Orhan Küçüksahin1,4
1 Department of Rheumatology, Ankara City Hospital, Ankara, Turkey
2 Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
3 Ministry of Health, Ankara, Turkey
4 Division of Rheumatology, Department of Internal Medicine, Yıldırım Beyazıt University, Ankara, Turkey
Abstract
Introduction: Colchicine is an ancient agent with well-known anti-inflammatory effects and commonly used in treatment of hyperinflammatory
conditions. It has been argued that colchicine could be an appropriate treatment option in COVID-19 to control hyperinflammatory response.
Here in this study, we aimed to investigate the impact of colchicine on outcomes of COVID-19 in our inpatient cohort.
Methodology: In this retrospective cohort study, hospitalized COVID-19 patients were investigated. Demographics, comorbidities, COVID19 symptoms, laboratory findings on admission and discharge, baseline and seventh day oxygenation status, rates of mortality, intensive care
unit admission, administration of other anti-inflammatory treatments and length of hospital stay were compared between patients who received
standard of care medications and who received colchicine additionally.
Results: Three hundred and thirty-six patients were included in the study (171 standard of care, 165 standard of care plus colchicine). The
median length of hospital stay in colchicine group was significantly shorter. Rates of admission to intensive care unit, anti-inflammatory
treatment administration and mortality did not differentiate between standard of care and colchicine groups. However, reduced rates of mortality
and ICU admission were observed in patients who received colchicine with a dose of 1 mg/day when compared to patients who received 0.5
mg/day.
Conclusions: Our study demonstrated that COVID-19 patients who received colchicine in addition to standard of care had shorter hospital stay.
Our results further support the use of colchicine in treatment of COVID-19, particularly with a dose of 1 mg/day.
Key words: COVID-19; colchicine; outcome; mortality; hospitalization.
J Infect Dev Ctries 2022; 16(1):57-62. doi:10.3855/jidc.14924
(Received 17 February 2021 – Accepted 14 June 2021)
Copyright © 2022 Karakaş et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit